Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock code: 688321.SH) (Chipscreen Biosciences) to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer (ES-SCLC). This cooperation is the specific practice of the Company in the 2.0 era of tumor immunity by adhering to the innovative drug development ideas of openness, diversity and win-win, cooperating with advantageous resources in the industry, deeply exploring the value of products. Leveraging on the advantages of the Chiauranib's dual immunotherapy for oncology and the uniqueness of Chiauranib as a multi-pathway selective kinase inhibitor, the combination therapy is believed to bring more effective clinical benefits to patients in relevant studies of diseases such as lung cancer.